Towards a consensus for the CMC aspects of N-of-1 oligonucleotide treatments
02 Dec 2025
CMC & Process Development
- What oligonucleotide chemistries are currently considered well-established to apply for N-of-1 treatments?
- What quality standards should be acceptable industry-wide for oligonucleotides?
- Which delivery technologies are considered to have sufficient maturity for N-of-1 treatments?
Industry Expert
